Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.
Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.
Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.
Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.
Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.
For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D., will take part in several virtual investor conferences in March 2021. Key presentations include:
- Cowen 41st Annual Healthcare Conference on March 1 at 2:40 PM EST.
- Barclays Global Healthcare Conference on March 9 at 11:30 AM EST.
- Oppenheimer 31st Annual Healthcare Conference on March 16 at 11:20 AM EDT.
Investors can access the webcasts on the Exelixis website, with replays available for 14 days.
Exelixis, Inc. (NASDAQ: EXEL) announced that the FDA has granted Breakthrough Therapy Designation for cabozantinib (CABOMETYX®) as a treatment for differentiated thyroid cancer (DTC) in patients who are radioactive iodine-refractory. This designation accelerates drug development for serious conditions. Preliminary data from the phase 3 COSMIC-311 trial showed cabozantinib significantly improved progression-free survival, with a 78% reduction in disease progression risk (HR 0.22; p<0.0001) compared to placebo. Exelixis plans to submit a regulatory application in 2021.
Exelixis, Inc. (Nasdaq: EXEL) announced that President and CEO Michael M. Morrissey, Ph.D., will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 1:00 PM EST. Due to the COVID-19 pandemic, the event will be virtual. Investors can access the webcast through the Exelixis website and are advised to join 15 minutes early. Exelixis is known for its oncology-focused biotechnology efforts, having developed four products and recognized for its rapid growth.
Exelixis announced positive phase 2 results for CABOMETYX® (cabozantinib) in treating metastatic papillary renal cell carcinoma (PRCC), outperforming sunitinib, the preferred therapy. The S1500 trial revealed a median progression-free survival (PFS) of 9.0 months for CABOMETYX compared to 5.6 months for sunitinib, with a statistically significant hazard ratio of 0.60 (p=0.019). Additionally, the objective response rate (ORR) was significantly higher at 23% for CABOMETYX versus 4% for sunitinib (p=0.010). Findings will be presented at ASCO GU on February 13, 2021, and published in The Lancet.
Exelixis reported positive final data from a phase 1 trial evaluating cabozantinib combined with nivolumab or nivolumab plus ipilimumab in patients with refractory metastatic genitourinary tumors. The trial showed an overall response rate (ORR) of 38%, with a complete response rate of 11.1% across 108 evaluable patients. Notably, the ORR was 62.5% in patients with metastatic renal cell carcinoma and 42.4% for metastatic urothelial carcinoma. The study supports further research into cabozantinib combinations, aiming to provide enhanced treatment options for challenging GU malignancies.
Exelixis, Inc. (Nasdaq: EXEL) reported 2020 financial results, highlighting total revenues of $987.5 million, a 2% increase from 2019. The fourth quarter alone brought in $270.1 million in revenues. While net product revenues for the year decreased to $741.6 million, collaboration revenues rose significantly to $246.0 million. The company's GAAP net income was $111.8 million, or $0.36 per share, down from $321 million in 2019. Exelixis anticipates 2021 revenues between $1.15 billion and $1.25 billion, fueled by ongoing regulatory efforts and pipeline advancements.
Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing on February 13, 2021, at 5:30 p.m. EST to discuss data from the ASCO GU 2021 symposium. The focus will be on cabozantinib clinical data, including results from the CheckMate -9ER trial, evaluating CABOMETYX in combination with OPDIVO for advanced renal cell carcinoma. The company aims to provide insights on additional studies involving cabozantinib for other genitourinary cancers. Interested participants can access the briefing via Exelixis’ website, with a replay available for one year.
Bristol Myers Squibb (BMY) and Exelixis (EXEL) reported compelling results from the Phase 3 CheckMate -9ER trial for advanced renal cell carcinoma (RCC). The combination of OPDIVO® (nivolumab) and CABOMETYX® (cabozantinib) demonstrated significant improvements in progression-free survival (PFS) at 17.0 months compared to sunitinib's 8.3 months (HR 0.52). Overall survival (OS) also improved with a 34% reduction in death risk (HR: 0.66). Patients reported enhanced quality of life with fewer adverse events. These findings will be presented at the ASCO 2021 Symposium.
Exelixis, Inc. (NASDAQ: EXEL) reported retrospective analysis results of CABOMETYX® in treating brain metastases from renal cell carcinoma (RCC). Findings, presented at ASCO GU, indicate a 61% intracranial response rate for patients with progressive intracranial disease and 57% for those without. Median overall survival was 14.7 months for progressing patients and 14.1 months for others. The safety profile aligns with known data. These results suggest CABOMETYX may benefit patients with challenging brain lesions in RCC.
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D., will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 11, 2021, at 11:30 AM EST. The event will be virtual due to COVID-19. Interested parties can access the webcast through the Exelixis website, where a replay will be available for 14 days post-event. Exelixis is known for its oncology-focused products, including CABOMETYX and COMETRIQ, and has been recognized as a leading biopharmaceutical company, ranking 17th in Fortune's 100 Fastest-Growing Companies.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is Exelixis Inc. known for?
What are the main products of Exelixis?
When was Cometriq first approved?
Who are the key partners of Exelixis?
What type of cancer is Cometriq used to treat?
What is Cabometyx used for?
Where can I find job opportunities at Exelixis?
How has the financial performance of Exelixis been?
What kind of research does Exelixis focus on?
What is the ticker symbol for Exelixis Inc.?
